GKOS Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.…
Industry Peers
Medical DevicesKey Statistics
About Glaukos (NYSE: GKOS)
›
Glaukos (NYSE: GKOS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,094 employees.
The shares were at 238.10 USD on 19 November 2026, up 164.5% over 52 weeks. Its 52-week range is 87.32 USD to 255.18 USD: the price is 6.7% below the high and 172.7% above the low.
Its market capitalisation is 14.09B USD.
Glaukos reports return on equity of -28.6%, an operating margin of -9.0% and revenue up 58.0% year over year.
It holds more cash than debt, a net cash position of 231.55M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 243.85 USD is 2.4% above the current price. The next earnings report is expected on 16 February 2027.